Moreover, activation of the MAPK14 signaling pathway has been previously shown to correlate with poor prognosis in GBM patients, increased tumor invasiveness, and aggressive phenotype [41, 42, 43, 44, 45]. This evidence concerns the gene MAPK14 and glioblastoma.